X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-14 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres,CEO,, Interim CFO | S - Sale | $10.72 | -100,000 | 3,805,858 | -3% | -$1,071,980 | ||||||
2024-06-12 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $147.21 | -15,000 | 6,946,164 | 0% | -$2,208,071 | ||||||
2024-06-14 | RGEN | Repligen Corp | Madaus Martin D | Dir | P - Purchase | $124.94 | +1,615 | 4,624 | +54% | +$201,776 | ||||||
| M | 2024-06-12 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $35.27 | -26,940 | 802,022 | -3% | -$950,174 | |||||
2024-06-14 | RGEN | Repligen Corp | Barthelemy Nicolas | Dir | P - Purchase | $125.45 | +1,200 | 4,668 | +35% | +$150,540 | ||||||
2024-06-14 | RGEN | Repligen Corp | Hunt Anthony | CEO | P - Purchase | $124.08 | +2,000 | 165,177 | +1% | +$248,160 | ||||||
| D | 2024-06-12 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $55.13 | -20,000 | 9,278 | -68% | -$1,102,668 | |||||
| D | 2024-06-14 | BCRX | Biocryst Pharmaceuticals Inc | Heggie Theresa | Dir | S - Sale+OE | $6.11 | -6,698 | 52,852 | -11% | -$40,925 | |||||
| DM | 2024-06-12 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $43.61 | -35,000 | 220,752 | -14% | -$1,526,350 | |||||
2024-06-13 | PROK | Prokidney Corp. | Legorreta Pablo G. | Dir, 10% | P - Purchase | $2.42 | +22,617,909 | 22,617,909 | New | +$54,735,340 | ||||||
2024-06-12 | KRBP | Kiromic Biopharma, Inc. | Misajon Pamela | Dir | P - Purchase | $3.28 | +1,610 | 28,811 | +6% | +$5,288 | ||||||
2024-06-12 | ZIVO | Zivo Bioscience, Inc. | Maggiore Christopher D. | Dir, 10% | P - Purchase | $7.97 | +3,764 | 465,027 | +1% | +$29,999 | ||||||
2024-06-11 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $8.45 | -11,447 | 7,188,563 | 0% | -$96,763 | ||||||
| M | 2024-06-11 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $7.17 | -630,148 | 6,458,373 | -9% | -$4,520,024 | |||||
| M | 2024-06-11 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $7.17 | -630,148 | 6,458,373 | -9% | -$4,520,024 | |||||
| D | 2024-06-12 | KOD | Kodiak Sciences Inc. | Borgeson John A. | See Remarks | S - Sale+OE | $2.92 | -1,558 | 179,544 | -1% | -$4,549 | |||||
2024-06-12 | TVGN | Tevogen Bio Holdings Inc. | Desai Kirti | CFO | P - Purchase | $0.82 | +3,000 | 9,699,186 | 0% | +$2,460 | ||||||
2024-06-13 | KRBP | Kiromic Biopharma, Inc. | Hungerford Brian | CFO | P - Purchase | $2.60 | +1,000 | 58,933 | +2% | +$2,600 | ||||||
| M | 2024-06-11 | HALO | Halozyme Therapeutics, Inc. | Posard Matthew L. | Dir | S - Sale | $50.32 | -20,000 | 99,755 | -17% | -$1,006,300 | |||||
| D | 2024-06-12 | JSPR | Jasper Therapeutics, Inc. | Mahal Jeetinder Singh | COO | S - Sale+OE | $24.16 | -900 | 25,009 | -3% | -$21,740 | |||||
| D | 2024-06-10 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale+OE | $17.65 | -5,000 | 170,695 | -3% | -$88,264 | |||||
2024-06-11 | KRBP | Kiromic Biopharma, Inc. | Nagel Michael | Dir | P - Purchase | $3.33 | +1,000 | 43,296 | +2% | +$3,330 | ||||||
2024-06-10 | KRBP | Kiromic Biopharma, Inc. | Misajon Pamela | Dir | P - Purchase | $2.93 | +1,701 | 27,201 | +7% | +$4,984 | ||||||
2024-06-12 | KRBP | Kiromic Biopharma, Inc. | Hungerford Brian | CFO | P - Purchase | $3.18 | +1,000 | 57,933 | +2% | +$3,180 | ||||||
| M | 2024-06-11 | KRBP | Kiromic Biopharma, Inc. | Bersani Pietro | CEO | P - Purchase | $3.26 | +6,000 | 138,845 | +5% | +$19,530 | |||||
2024-06-11 | VIR | Vir Biotechnology, Inc. | Ramasastry Saira | Dir | S - Sale | $10.95 | -4,000 | 14,619 | -21% | -$43,789 | ||||||
2024-06-10 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $3.36 | +1,000 | 38,245 | +3% | +$3,360 | ||||||
| M | 2024-06-07 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.94 | +405,500 | 1,786,412 | +29% | +$381,170 | |||||
2024-06-11 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $175.76 | -50,000 | 3,253,144 | -2% | -$8,788,062 | ||||||
2024-06-11 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $175.76 | -50,000 | 3,253,144 | -2% | -$8,788,062 | ||||||
2024-06-11 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $148.34 | -202,832 | 11,410,137 | -2% | -$30,087,339 | ||||||
2024-06-07 | CDTX | Cidara Therapeutics, Inc. | Stein Jeffrey | Pres, CEO | P - Purchase | $13.21 | +8,000 | 84,564 | +10% | +$105,680 | ||||||
| D | 2024-06-10 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $11.79 | -93 | 6,721 | -1% | -$1,096 | |||||
| D | 2024-06-10 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $11.79 | -50 | 76,490 | 0% | -$590 | |||||
| D | 2024-06-10 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $148.09 | -5,178 | 15,947 | -25% | -$766,785 | |||||
2024-06-07 | SLDB | Solid Biosciences Inc. | Kahn Clare | Dir | P - Purchase | $7.67 | +1,100 | 1,100 | New | +$8,442 | ||||||
2024-06-07 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $7.50 | -15,881 | 117,131 | -12% | -$119,108 | ||||||
2024-06-06 | DNLI | Denali Therapeutics Inc. | Cook Jennifer E. | Dir | S - Sale | $21.73 | -1,458 | 20,038 | -7% | -$31,682 | ||||||
2024-06-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $51.33 | -276 | 80,160 | 0% | -$14,167 | ||||||
2024-06-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $51.33 | -242 | 39,945 | -1% | -$12,422 | ||||||
2024-06-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $51.33 | -918 | 90,593 | -1% | -$47,120 | ||||||
| D | 2024-06-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $51.33 | -2,408 | 507,578 | 0% | -$123,600 | |||||
2024-06-05 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $151.25 | -15,000 | 11,612,969 | 0% | -$2,268,804 | ||||||
| D | 2024-06-07 | KYMR | Kymera Therapeutics, Inc. | Horobin Joanna | Dir | S - Sale+OE | $32.99 | -8,500 | 0 | -100% | -$280,400 | |||||
2024-06-05 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $17.32 | +57,549 | 1,150,410 | +5% | +$997,024 | ||||||
2024-06-05 | TVGN | Tevogen Bio Holdings Inc. | Saadi Ryan H. | CEO, 10% | P - Purchase | $0.77 | +2,607 | 118,446,583 | 0% | +$2,000 | ||||||
| DM | 2024-06-05 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $8.71 | -100,000 | 708,738 | -12% | -$871,000 | |||||
2024-06-04 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale | $22.00 | -8,287 | 349,499 | -2% | -$182,314 | ||||||
2024-06-05 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $3.00 | -5,000 | 375,092 | -1% | -$14,989 | ||||||
2024-06-04 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $5.50 | -12,191 | 315,279 | -4% | -$66,997 | ||||||
2024-06-04 | EDIT | Editas Medicine, Inc. | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | S - Sale | $5.50 | -511 | 141,032 | 0% | -$2,808 | ||||||
2024-06-05 | ATYR | Atyr Pharma Inc | Denyes Nancy | GC | P - Purchase | $1.86 | +5,000 | 22,267 | +29% | +$9,276 | ||||||
| M | 2024-06-03 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $6.70 | -80,909 | 432,425 | -16% | -$542,448 | |||||
| D | 2024-06-03 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $0.55 | -13,440 | 178,832 | -7% | -$7,379 | |||||
| D | 2024-06-03 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $0.55 | -48,866 | 984,662 | -5% | -$26,827 | |||||
| D | 2024-06-03 | PCVX | Vaxcyte, Inc. | Gilbert Halley E | Dir | S - Sale+OE | $73.00 | -18,200 | 5,625 | -76% | -$1,328,600 | |||||
| D | 2024-06-03 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $72.06 | -1,667 | 31,161 | -5% | -$120,127 | |||||
2024-06-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $71.99 | -3,000 | 213,503 | -1% | -$215,961 | ||||||
2024-06-03 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale | $72.06 | -2,616 | 623,634 | 0% | -$188,512 | ||||||
| D | 2024-06-03 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $39.99 | -7,500 | 848,774 | -1% | -$299,942 | |||||
2024-06-03 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $4.04 | -1,207 | 15,554 | -7% | -$4,876 | ||||||
2024-06-03 | SWTX | Springworks Therapeutics, Inc. | Islam Saqib | CEO | S - Sale | $39.90 | -49,000 | 1,112,368 | -4% | -$1,955,113 | ||||||
2024-06-03 | SWTX | Springworks Therapeutics, Inc. | Hambleton Julie | Dir | S - Sale | $40.03 | -4,648 | 4,095 | -53% | -$186,048 | ||||||
2024-06-03 | SWTX | Springworks Therapeutics, Inc. | Edris Badreddin | COO | S - Sale | $40.07 | -20,000 | 249,600 | -7% | -$801,372 | ||||||
2024-06-04 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | P - Purchase | $6.35 | +2,362 | 7,088,521 | 0% | +$14,999 | ||||||
2024-06-04 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | P - Purchase | $6.35 | +2,362 | 7,088,521 | 0% | +$14,999 | ||||||
| M | 2024-05-31 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $7.82 | -1,001,852 | 7,086,159 | -12% | -$7,832,200 | |||||
| M | 2024-05-31 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $7.82 | -1,001,852 | 7,086,159 | -12% | -$7,832,200 | |||||
2024-06-03 | VOR | Vor Biopharma Inc. | Attar Eyal C. | Chief Medical Officer | S - Sale | $1.39 | -14,645 | 96,063 | -13% | -$20,357 | ||||||
2024-06-03 | ALEC | Alector, Inc. | Romano Gary | Chief Medical Officer | S - Sale | $4.80 | -8,040 | 188,273 | -4% | -$38,582 | ||||||
2024-06-03 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $4.80 | -13,206 | 305,641 | -4% | -$63,373 | ||||||
2024-06-03 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $4.80 | -25,135 | 5,905,620 | 0% | -$120,618 | ||||||
2024-06-03 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $4.80 | -6,920 | 138,037 | -5% | -$33,208 | ||||||
| M | 2024-05-31 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $17.18 | +286,786 | 1,092,861 | +36% | +$4,927,580 | |||||
| D | 2024-06-03 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $140.72 | -691 | 6,506 | -10% | -$97,237 | |||||
| D | 2024-06-03 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $140.72 | -339 | 1,628,138 | 0% | -$47,704 | |||||
| D | 2024-06-03 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $140.72 | -122 | 10,878 | -1% | -$17,168 | |||||
| D | 2024-05-31 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $136.55 | -273 | 7,507 | -4% | -$37,278 | |||||
2024-06-03 | BLUE | Bluebird Bio, Inc. | Klima Thomas J | See Remarks | S - Sale | $0.97 | -3,834 | 121,006 | -3% | -$3,726 | ||||||
2024-05-30 | CRGX | Cargo Therapeutics, Inc. | Samsara Biocapital Gp, LLC | 10% | P - Purchase | $17.00 | +294,000 | 4,415,689 | +7% | +$4,998,000 | ||||||
| D | 2024-05-30 | RXRX | Recursion Pharmaceuticals, Inc. | Marriott Tina | Pres, COO | S - Sale+OE | $8.78 | -3,000 | 535,457 | -1% | -$26,325 | |||||
2024-06-03 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | S - Sale | $6.76 | -2,431 | 187,471 | -1% | -$16,434 | ||||||
2024-06-03 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | P - Purchase | $7.37 | +2,050 | 8,088,011 | 0% | +$15,109 | ||||||
2024-06-03 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | P - Purchase | $7.37 | +2,050 | 8,088,011 | 0% | +$15,109 | ||||||
| DM | 2024-05-30 | HUMA | Humacyte, Inc. | Prichard Heather Ledbetter | COO | S - Sale+OE | $8.15 | -191,511 | 0 | -100% | -$1,561,605 | |||||
2024-05-30 | LIFE | Atyr Pharma Inc | Coughlin Timothy | Dir | P - Purchase | $1.75 | +50,000 | 56,000 | +833% | +$87,500 | ||||||
2024-05-30 | ALLO | Allogene Therapeutics, Inc. | Humer Franz B | Dir | S - Sale | $2.34 | -11,200 | 255,253 | -4% | -$26,181 | ||||||
2024-05-31 | LIFE | Atyr Pharma Inc | Broadfoot Jill Marie | CFO | P - Purchase | $1.79 | +5,000 | 27,960 | +22% | +$8,950 | ||||||
2024-05-31 | LIFE | Atyr Pharma Inc | Shukla Sanjay | Pres, CEO | P - Purchase | $1.81 | +20,000 | 136,548 | +17% | +$36,140 | ||||||
2024-05-29 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $145.08 | -20,000 | 11,627,969 | 0% | -$2,901,585 | ||||||
| M | 2024-05-29 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.92 | +10,434 | 1,380,912 | +1% | +$9,580 | |||||
2024-05-29 | IVVD | Invivyd, Inc. | McGuire Terrance | Dir | S - Sale | $1.66 | -112,381 | 8,419,319 | -1% | -$186,575 | ||||||
2024-05-30 | BCRX | Biocryst Pharmaceuticals Inc | Levin Alan G | Dir | P - Purchase | $6.36 | +7,861 | 44,951 | +21% | +$49,996 | ||||||
| M | 2024-05-30 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $2.92 | -15,054 | 108,696 | -12% | -$44,008 | |||||
| M | 2024-05-28 | EXEL | Exelixis, Inc. | Johnson David Edward | Dir | P - Purchase | $20.55 | +425,000 | 1,543,906 | +38% | +$8,733,955 | |||||
2024-05-28 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $9.17 | -11,447 | 7,186,913 | 0% | -$104,943 | ||||||
| D | 2024-05-28 | INBX | Inhibrx, Inc. | Eckelman Brendan P. | Chief Scientific Officer | S - Sale+OE | $34.30 | -300,000 | 0 | -100% | -$10,290,000 | |||||
| D | 2024-05-29 | NBIX | Neurocrine Biosciences Inc | Sherwin Stephen A | Dir | S - Sale+OE | $133.46 | -40,000 | 26,504 | -60% | -$5,338,565 | |||||
| D | 2024-05-29 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $144.51 | -183 | 5,871 | -3% | -$26,444 | |||||
| D | 2024-05-29 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $144.51 | -183 | 10,768 | -2% | -$26,444 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |